Table 4.
The novel scoring model (p-TACE model) for pre-treatment prediction of TACE refractoriness
| Risk factors | Grade | Score | |||
|---|---|---|---|---|---|
| Vascularization pattern | Type 1/2 | 0 | |||
| Type 3/4 | 5.5 | ||||
| ALBI grade | 1 | 0 | |||
| 2/3 | 3.5 | ||||
| AFP level, ng/mL | ~80 | 0 | |||
| ~4000 | 3 | ||||
| >4000 | 5 | Scoring model grade (score) | Estimated risk of TACE refractoriness | ||
| γ-GT level, U/L | ~50 | 0 | |||
| ~75 | 1 | Grade 1 (<4) | 15% or less | ||
| ~135 | 2 | Grade 2 (≥4) | appr. 30% | ||
| >135 | 3.5 | Grade 3 (≥7) | appr. 40% | ||
| Major tumor size, cm | ~5 | 0 | Grade 4 (≥10) | appr. 60% | |
| >5 | 2 | Grade 5 (≥13) | appr. 75% | ||
| Total | range 0 ~ 19.5 | Grade 6 (≥16) | 85% or more |
TACE: transarterial chemoembolization; ALBI grade: albumin-bilirubin grade; AFP: alpha-fetoprotein; γ-GT, γ- glutamyl transpeptidase